Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 29, 2026Journal of Clinical Oncology

A prospective observational study to compare the efficacy, time toxicity, and cost of conventional 3+7 regimen versus azacitidine + venetoclax (AZA + VEN) as induction therapy in patients with acute myeloid leukemia (AML).

View Full Paper
Ask AI
Bookmark
Share

Authors

MSManju SengarTata Memorial HospitalAVArvind VaidyanathanHomi Bhabha National InstituteHJHasmukh JainTata Memorial Hospital

Discussion

Loading...

Member takes

Implication

Prospective observational study compares AZA+VEN and 3+7 induction therapies in AML, suggesting a safer and less costly alternative for high-risk patients.

Key Points

  • The study aims to compare the efficacy, toxicity, and cost of AZA+VEN versus the 3+7 regimen as induction therapy in acute myeloid leukemia patients.
  • Conducted a prospective observational study with de-novo AML patients aged ≥18 years.
  • Enrolled consecutive patients planned for either 3+7 or AZA+VEN treatment after informed consent.
  • Primary endpoint was induction mortality, with secondary endpoints including toxicity, treatment cost, and complete response rates.
  • Induction mortality was similar: 8.2% for 3+7 vs 7.5% for AZA+VEN.
  • Toxicities were significantly higher with 3+7, including febrile neutropenia (95.9% vs 79.7%) and new-onset bacterial infections (49.3% vs 19.0%).
  • Median treatment cost was lower for AZA+VEN (184,694 INR vs 227,790 INR for 3+7) and time toxicity was less (19.0 days vs 26.0 days).

Cite This Study

Sengar et al. (2026) studied this question.

synapsesocial.com/papers/6a192e79fab5b468c4417a4ehttps://doi.org/10.1200/jco.2026.44.16_suppl.6511
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes of 7+3 versus azacitidine/venetoclax in CML transformed to AML.2026
  2. 2Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia2025 · 35 citations
  3. 3Comparing the efficacy and safety of the ABC-14 regimen (Azacitidine, Venetoclax, and Chidamide) with traditional “3+7” intensive induction regimen or AB-14 regimen (Venetoclax Combined with Azacitidine) in newly diagnosed AML: Study protocol for a prospective, multicenter, randomized, open-label clinical trial2025
  4. 4Addition of Venetoclax to Azacitidine Did Not Improve Survival in Acute Myeloid Leukemia and Was Not Well Tolerated: Real World Experience2026 · 1 citations
  5. 5Dose-adjusted treatment with venetoclax for 7 days and 5-azacitidine or decitabine in patients with Acute Myeloid Leukemia or higher risk myelodysplastic neoplasms2025